Sylvie Assadourian

1.7k total citations
33 papers, 1.3k citations indexed

About

Sylvie Assadourian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sylvie Assadourian has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Sylvie Assadourian's work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer therapeutics and mechanisms (6 papers). Sylvie Assadourian is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer therapeutics and mechanisms (6 papers). Sylvie Assadourian collaborates with scholars based in France, United States and Italy. Sylvie Assadourian's co-authors include Eric Van Cutsem, Vladimir Moiseyenko, M Fodor, Alejandro Majlis, Yee Chao, Jaffer A. Ajani, Sergei Tjulandin, Sebastião Cabral Filho, Jean‐Pierre Lotz and Xavier Pivot and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Sylvie Assadourian

33 papers receiving 1.3k citations

Peers

Countries citing papers authored by Sylvie Assadourian

Since Specialization

Citations

This map shows the geographic impact of Sylvie Assadourian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Assadourian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Assadourian more than expected).

Fields of papers citing papers by Sylvie Assadourian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Assadourian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Assadourian. The network helps show where Sylvie Assadourian may publish in the future.

Co-authorship network of co-authors of Sylvie Assadourian

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Assadourian. A scholar is included among the top collaborators of Sylvie Assadourian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Assadourian. Sylvie Assadourian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis 2020 ·Leukemia ·Meletios Α. Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, (unknown), Dorothée Sémiond, Helgi van de Velde, Kwee Yong	44
2	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer 2017 ·Oncotarget ·Kohei Shitara, Tae Min Kim, Tomoya Yokota, Masahiro Goto, Taroh Satoh, Jin Hee Ahn, Hyo Song Kim, Sylvie Assadourian, (unknown), (unknown), Satoshi Hamauchi, Toshihiro Kudo, (unknown), Yung‐Jue Bang	24
3	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification 2017 ·European Journal of Cancer ·Eric Angevin, Gianluca Spitaleri, Jordi Rodón, Katia Dotti, Nicolás Isambert, Stefania Salvagni, Víctor Moreno, Sylvie Assadourian, (unknown), (unknown), Antoine Hollebecque, Analía Azaro, Alice Hervieu, Karim Rihawi, Filippo de Marinis	35
4	Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies 2015 ·Oncology ·Rastislav Bahleda, Jackie Baker, Christophe Massard, S. Gadgeel, Jane E. Rogers, Hassan Izzedine, Éric Deutsch, (unknown), (unknown), Emmanuelle Boëlle, Sylvie Assadourian, Jean‐Charles Soria, Jaffer A. Ajani	2
5	A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results. 2014 ·Journal of Clinical Oncology ·Eric Angevin, Gianluca Spitaleri, Antoine Hollebecque, Tommaso De Pas, Jean‐Charles Soria, (unknown), (unknown), Sylvie Assadourian, Filippo de Marinis	4
6	Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer 2013 ·European Journal of Cancer ·Philippe Rougier, Hanno Riess, Robert Manges, Petr Karásek, Yves Humblet, C. Barone, Armando Santoro, Sylvie Assadourian, Laurence Hatteville, Philip A. Philip	145
7	Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study 2013 ·European Journal of Cancer ·David Khayat, Sabine Tejpar, Jean‐Philippe Spano, Chris Verslype, (unknown), Vincent Vandecaveye, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), Eric Van Cutsem	14
8	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Nicolás Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, P. Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), V. Trillet-Lenoir	31
9	Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours 2012 ·European Journal of Cancer ·Eric Van Cutsem, David Khayat, Chris Verslype, Bertrand Billemont, Sabine Tejpar, Jean‐Baptiste Méric, Karen Soussan-Lazard, Sylvie Assadourian, (unknown), Olivier Rixe	27
10	Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours 2012 ·British Journal of Cancer ·Gilles Freyer, Nicolás Isambert, Benoît You, Sylvie Zanetta, Claire Falandry, Laure Favier, V. Trillet-Lenoir, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), P. Fumoleau	17
11	Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study 2012 ·European Journal of Cancer ·Véronique Dièras, Alain Lortholary, Valérie Laurence, R. Delva, V. Girre, Alain Livartowski, Sylvie Assadourian, Dorothée Sémiond, Jean‐Yves Pierga	47
12	A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients 2008 ·Annals of Oncology ·Xavier Pivot, P. Koralewski, Jorge Hidalgo, Arlene Chan, Anthony Gonçalvès, Gilberto Schwartsmann, Sylvie Assadourian, Jean‐Pierre Lotz	148
13	A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Française d’Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG) 2008 ·European Journal of Cancer ·Gilles Vassal, Francesco Giammarile, (unknown), Birgit Geoerger, D. Couanet, Jean Michon, (unknown), Matthias Schell, Anne Geoffray, Jean‐Claude Gentet, F. Pichon, Hervé Rubie, Laura A. Cisar, Sylvie Assadourian, Bruce Morland	29
14	A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours 2006 ·Annals of Oncology ·Herlinde Dumez, Ahmad Awada, Martine Piccart, Sylvie Assadourian, Dorothée Sémiond, G. Guetens, Gert De Boeck, R. A. A. Maes, E. A. de Bruijn, A. van Oosterom	15
15	Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a combination phase I clinical trial of patients with advanced solid tumors 2006 ·Journal of Clinical Oncology ·O. Rixe, Chris Verslype, (unknown), Sabine Tejpar, Joël S. Bloch, (unknown), D. Khayat, Eric S. Furfine, Sylvie Assadourian, Eric Van Cutsem	12
16	Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors 2005 ·Journal of Clinical Oncology ·Otto Soepenberg, Herlinde Dumez, Jaap Verweij, Dorothée Sémiond, (unknown), Ferry A.L.M. Eskens, (unknown), (unknown), Sylvie Assadourian, Ger‐Jan Sanderink, Alex Sparreboom, A.T. van Oosterom	25
17	Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma 2005 ·Journal of Clinical Oncology ·Jaffer A. Ajani, M Fodor, Sergei Tjulandin, Vladimir Moiseyenko, Yee Chao, Sebastião Cabral Filho, Alejandro Majlis, Sylvie Assadourian, Eric Van Cutsem	179
18	Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) 2005 ·Journal of Clinical Oncology ·Eric Van Cutsem, Roberto Labianca, D Hossfeld, G. Bodoky, A Roth, Enrique Aranda, Bernard Nordlinger, Sylvie Assadourian, (unknown), David Cunningham	93
19	Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure 2002 ·British Journal of Cancer ·Jacques Bonneterre, Henri Roché, Alain Monnier, Jean‐Paul Guastalla, M. Namer, P. Fargeot, Sylvie Assadourian	106
20	A dose finding and pharmacokinetic study of docetaxel (TXT) and methotrexate (MTX) in patients with epithelial cancer 1999 ·European Journal of Cancer ·Sylvie Zanetta, Aline Guillot, C Ardiet, Brigitte Tranchand, A Dumortier, E Bernard, (unknown), Sylvie Assadourian, J.P. Droz	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact